IOVA
Iovance Biotherapeutics Inc
A California biotech that turns a patient's own tumor-fighting immune cells into a cancer treatment, sold as the drug Amtagvi for advanced melanoma. It started in 2007 as Genesis Biopharma, later merged with Lion Biotechnologies, and took the name Iovance in 2017. Its Amtagvi became the first cell therapy the FDA approved for a solid tumor cancer in 2024.
CUSIP: 462260100HealthcareUS1 holder
Total Value
$253.0K
Total Shares
34.9K
Net Share Change
-748.1K
Activity
1 selling
Investor
Value
Shares
Weight
Change
